Beyond the Retina: The Emerging Potential of the Suprachoroidal Space
"Unlock new possibilities in eye health: Discover how advanced imaging and targeted drug delivery are transforming our understanding and treatment of retinal diseases through the suprachoroidal space."
The suprachoroidal space (SCS), a long-recognized potential space between the choroid and sclera, is rapidly becoming a focal point in ophthalmology. Traditionally, this space was only observable through histology or, indirectly, via ultrasonography in specific pathological conditions. However, recent advancements in optical coherence tomography (OCT) imaging are changing this landscape, offering detailed in vivo visualization.
OCT, particularly enhanced depth imaging (EDI-OCT) and swept-source OCT, has revolutionized retinal imaging, allowing clinicians to see beyond the retina and into the underlying layers. These techniques enable the identification of changes in choroidal thickness associated with various retinal diseases, including central serous chorioretinopathy, polypoidal choroidal vasculopathy, myopic degeneration, and age-related macular degeneration (AMD).
Now, with the ability to accurately image the SCS in living eyes, researchers are gaining new insights into its role in both healthy and diseased states. This enhanced visualization not only aids in diagnosis and monitoring but also opens doors for innovative medical and surgical interventions, positioning the SCS as a key area of interest for retinal specialists.
Measuring an Emerging Route
The suprachoroidal space (SCS) is being investigated as an emerging route for drug delivery and gene therapy. A large cohort study of healthy human eyes analyzed demographic and ocular factors associated with SCS visibility and thickness using enhanced-depth imaging optical coherence tomography (EDI-OCT). Related work established a nomogram for SCS measurements, underscoring the importance of accounting for anatomical variation when evaluating the macular SCS.
Beyond Conventional Delivery
The SCS is a potential space between the sclera and choroid that extends around the posterior segment and can target the choroid, retinal pigment epithelium, and nearby tissues. Intravitreal delivery remains attractive because it is an inexpensive in-office procedure, can provide therapeutic levels for weeks to months, and has an excellent safety profile, although endophthalmitis remains a rare major complication. In contrast, subretinal delivery of AAV8 using a transscleral approach produced robust focal transduction near the injection site, illustrating how delivery method influences the distribution and reach of treatment.
Imaging the Suprachoroidal Space: What are we seeing?
While studies on choroidal thickness often define the inner border of the sclera as the choroid's outer boundary, the presence of a hyporeflective band between the choroid and sclera has been noted. This band, now identified as the SCS, can introduce variability in choroidal thickness measurements. Advanced OCT techniques are essential for accurately visualizing and measuring this space.
- AMD: Detected in 20-50% of eyes with age-related macular degeneration.
- Macular Holes/Epiretinal Membranes: Found in 50-60% of patients.
- Central Serous Chorioretinopathy: Fluid loculation in the outer choroid is seen in approximately 65% of eyes.
Imaging and Therapeutic Expansion
Swept-source OCT research suggests that the SCS could become a routine component of diagnosis, monitoring, and treatment for retinal diseases, but the reported results came from a small number of patients and require validation with larger studies, additional devices, and multiple observers. A separate preclinical study reported that the SCS can be visualized with EDI-OCT in about 45% of healthy subjects, particularly in hyperopes. Together, these findings point to growing clinical interest while highlighting that SCS visibility and imaging performance remain important research questions.
Promise Without Full Validation
OCT has transformed ophthalmology by enabling detailed in vivo imaging of retinal structures and, with technological advances, the layers beneath the retina. However, the available commentary presents the SCS primarily as an emerging opportunity rather than a fully established clinical pathway. One review states that the SCS is likely to become a common route for drug delivery for retinal diseases, which is a projection rather than evidence that this transition has already occurred.
A Broader Therapeutic Platform
The 2015 opinion piece, published in versions by DovePress and Taylor & Francis, describes advances in imaging that have made the SCS demonstrable and clinically relevant to retinal pathologies. It also reviews the SCS as a potential route for drug delivery and as a site for innovative surgical techniques. The two versions support the same broad comparison: the SCS is being considered not only for medication delivery but also for imaging-guided understanding of disease and surgical innovation.
The Future of the Suprachoroidal Space: A New Frontier in Eye Care
The suprachoroidal space is garnering increased attention, and its importance in the diagnosis and treatment of various retinal conditions is becoming more evident. Recent technological advancements have enabled clear imaging of the SCS, shedding light on its variability in aging, health, and disease.
From Potential Space to Potential
The reviewed commentary frames the SCS as a space whose clinical relevance has grown alongside advances in ocular imaging. It connects improved visualization of the SCS with implications for retinal pathologies and possible therapeutic applications. Because the source is an opinion piece, its conclusions describe an expanding field of potential rather than definitive clinical consensus.
Toward More Precise Access
Ultrasonography and OCT are the main methods used to evaluate the SCS in clinical practice, and both are expected to improve. A 2026 report on Everads' suprachoroidal injector described favorable first-in-human safety and tolerability data, with thermal imaging indicating posteriorly directed drug distribution toward targeted retinal areas. These developments suggest that future progress may depend on combining better imaging with devices designed for more controlled suprachoroidal delivery.
Evidence in Clinical Practice
In a real-world cohort, suprachoroidal triamcinolone acetonide injections were associated with robust anatomical improvement in patients with inflammation-related macular edema. The report also described a favorable intraocular-pressure profile and prolonged durability across patients. These findings provide practice-based evidence for evaluating suprachoroidal treatment beyond controlled experimental settings, although the source snippet does not provide the cohort size or detailed outcome values.
Beyond imaging, the SCS is emerging as a promising target for both drug delivery and surgical interventions. From microneedles for targeted drug administration to novel retinal prostheses, various innovative devices are being developed to leverage this space.
In the future, the SCS will likely become a routine consideration in the diagnosis, monitoring, and treatment of retinal diseases. As research continues to uncover its potential, clinicians should familiarize themselves with identifying and characterizing the SCS in OCT scans, paving the way for new insights and clinically significant advancements in eye care.